Antagonism of a PCP drug discrimination by hallucinogens and related drugs.
W B West, A Lou, K Pechersky, M E Chachich, J B Appel
Neuropsychopharmacology June 2000 DOI: 10.1016/s0893-133x(99)00163-3 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational study Peer reviewed |
|---|---|
| Population | Rats |
| Interventions | LSD DOM DMT lisuride spiperone ritanserin |
| Dose | PCP 2.5 mg/kg; LSD 0.32 mg/kg; DOM 4.0 mg/kg; DMT 8.0 mg/kg; lisuride 0.4 mg/kg |
| Key findings | LSD (0.32 mg/kg) and DOM (4.0 mg/kg) completely blocked the PCP cue, while DMT (8.0 mg/kg) and lisuride (0.4 mg/kg) partially blocked it. Spiperone and ritanserin had no effect. The authors propose that these effects are mediated by agonist actions at 5-HT2 receptors. |
Abstract
Drugs such as PCP and MK-801 can cause psychotic reactions in humans by antagonizing NMDA receptors. This action is ultimately toxic to certain cortical neurons and may be one mechanism underlying neurodegenerative diseases, including schizophrenia. It has been reported that hallucinogens such as LSD, DOM, and DOI can block the neurotoxic effects of NMDA antagonists, possibly by activating inhibitory 5-HT2A receptors on GABAergic interneurons that normally inhibit glutamatergic projections to the retrosplenial and cingulate cortexes. The purpose of this experiment was to determine the extent to which similar drugs might also alter the behavioral effects of one NMDA antagonist, PCP. Rats were trained to discriminate this compound (2.5 mg/kg) from saline and were then given a series of antagonist tests. It was found that LSD (0.32 mg/kg) and DOM (4.0 mg/kg) blocked the PCP cue completely; DMT (8.0 mg/kg) and a structural congener of LSD, lisuride (LHM; 0.4 mg/kg), blocked the effects of PCP partially. The 5-HT/DA antagonists spiperone and ritanserin had no effect on the PCP cue. These data suggest that LSD, DOM, and, less effectively, DMT and LHM can block the behavioral as well as the neurotoxic effects of NMDA antagonists most likely through agonist actions at 5-HT2 receptors.
Citations in the library
Cited by 9
- Transcriptome Fingerprints Distinguish Hallucinogenic and Nonhallucinogenic 5-Hydroxytryptamine 2A Receptor Agonist Effects in Mouse Somatosensory Cortex Journal of Neuroscience October 1, 2003
- Neuropharmacology of N,N-dimethyltryptamine Brain Research Bulletin April 30, 2016
- Exploring DMT: Endogenous role and therapeutic potential. Neuropharmacology May 1, 2025
- Molecular Pathways of the Therapeutic Effects of Ayahuasca, a Botanical Psychedelic and Potential Rapid-Acting Antidepressant Biomolecules November 2, 2022
- Some distorted thoughts about ketamine as a psychedelic and a novel hypothesis based on NMDA receptor-mediated synaptic plasticity. Neuropharmacology November 2018
and 4 more in the library
Cites 13
- Recent advances in the phencyclidine model of schizophrenia American Journal of Psychiatry October 1, 1991
- Study of a New Schizophrenomimetic Drug—Sernyl Archives of Neurology And Psychiatry March 1, 1959
- NMDA Antagonist Neurotoxicity: Mechanism and Prevention Science December 6, 1991
- Agonist Properties of N,N-Dimethyltryptamine at Serotonin 5-HT2A and 5-HT2C Receptors Pharmacology, Biochemistry, and Behavior November 1, 1998
- Neuropharmacological reassessment of the discriminative stimulus properties ofd-lysergic acid diethylamide (LSD) Psychopharmacology 1987
and 8 more in the library